AzTrials
AzTrials

Paroxysmal Atrial FibrillationNCT04022954

HD Mapping of Atrial Fibrillation in Asia Pacific

An observational study of Paroxysmal Atrial Fibrillation and Persistent Atrial Fibrillation, run by Abbott Medical Devices at 15 sites in 5 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study is to quantify and characterize the outcomes of radiofrequency (RF) ablation after, and the utility of, electroanatomical mapping with the market-released HD mapping catheters Inquiry™ AFocusII™ Double Loop and Advisor™ HD Grid, Sensor Enabled™ with the EnSite Cardiac Mapping System and the… Read more about this study

Who is it for?
Ages 18 to 99 years
What is being tested?
Catheter ablation
Type of treatment
Medical device
How many people
200 participants
Where
15 sitesin 5 countries
Study dates
11 Sep 2019to 13 Aug 2021
How long will I take part?
12 Months
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The analysis population used for all endpoints will include all subjects who have signed the Informed Consent Form and have undergone the electroanatomical mapping procedure using one of the specified HD mapping catheters and received RF ablation as specified in the protocol. If any device used during the procedure is used off-label, the subject will be excluded from non-safety related endpoint analysis and any additional evaluations

Who may be able to join

  • Subject must provide written informed consent for study participation and willing and able to comply with the protocol described evaluations and follow up schedule
  • Subject must be over 18 years of age. (In Japan, the subject must be of 20 years of age or older)
  • Subject is diagnosed with AF as defined by:
  • Documented symptomatic paroxysmal AF defined as AF that terminates spontaneously or with intervention within 7 days of onset
  • Documented symptomatic persistent AF defined as continuous atrial fibrillation that is sustained beyond 7 days but less than 12 months
  • Subject is indicated for cardiac electroanatomical mapping and RF ablation procedure to treat AF
  • Subject is planned to have electroanatomical mapping performed with the HD mapping catheters under investigation

Who cannot join

  • Previous ablation or surgery in the left atria
  • Implanted left atrial appendage occluder
  • Implanted mitral or tricuspid valve replacement
  • Implanted cardiac defibrillator (ICD)
  • Participation in another clinical investigation that may confound the results of this study
  • Pregnant or nursing
  • Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
  • Life expectancy less than 12 months

Trial locations and contacts

15 sites in 5 countries.

15 sites in 5 countries

Japan8 sites
  • Yokosuka Kyosai Hospital

    Kanagawa

  • Kokura Memorial Hospital

    Kitakyushu-shi, Fukuoka, 802-8555

  • Kyoto University Hospital

    Kyoto, 606-8507

  • Ogaki Municipal Hospital

    Ōgaki

  • Saga University Hospital

    Saga

  • Kitasato University Hospital

    Sagamihara

  • Kyorin University Hospital

    Tama

  • University of Tsukuba Hospital

    Tsukuba, Ibaraki, 305-8576

Other trials in Japan

China2 sites
  • Sir Run Run Shaw Hospital

    Hangzhou

  • The Second Affiliated Hospital of Xian Jiaotong University

    Xi'an

Other trials in China

South Korea2 sites
  • Korea University Anam Hospital

    Seoul

  • Severance Hospital

    Seoul

Other trials in South Korea

Taiwan2 sites
  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City

  • Taipei Veterans General Hospital (VGH)

    Taipei

Other trials in Taiwan

Hong Kong1 site
  • Prince of Wales Hospital

    Hong Kong

Other trials in Hong Kong

About this study

Official title: HD Mapping Observational Study - Asia Pacific

The aim of this study is to quantify and characterize the outcomes of radiofrequency (RF) ablation after, and the utility of, electroanatomical mapping with the market-released HD mapping catheters Inquiry™ AFocusII™ Double Loop and Advisor™ HD Grid, Sensor Enabled™ with the EnSite Cardiac Mapping System and the EnSite Automap module in subjects with AF in the real-world environment of the Asian population.

Being tested
Catheter ablation
Medical subject headings
Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Catheter ablationDevice

    Inquiry AFocusII Double Loop and Advisor HD Grid, Sensor Enabled

Study groups in NCT04022954
Study groupRoleWhat they receive
Inquiry™ AFocusII™ Double LoopThe Inquiry™ AFocus™ catheters are for recording intracardiac signals and cardiac stimulation during diagnostic electrophysiological studies. The Inquiry™ AFocus™ catheters are for use in mapping atrial regions of the heart.
Receives: Device: Catheter ablation
Advisor™ HD Grid, Sensor Enabled™The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart with recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart.
Receives: Device: Catheter ablation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Acute Success of RF Ablation After Electroanatomical Mapping With HD Mapping Catheters.

    The rate of acute success was defined as the proportion of subjects who receive HD mapping and RF energy delivery resulting in acute termination of clinical arrhythmia, defined by termination to SR (or AT if being treated for PersAF) or non-inducibility of clinical arrhythmia after ablation (cardioversion allowed prior to inducibility attempt). This measure is presented here as the number of participants with acute success, and the associated percentage of subjects (proportion * 100%) with acute success is also displayed as the result of an automatic calculation.

    Measured: End of Procedure

  2. Number of Participants With Clinical Long-Term Success

    Freedom from all atrial arrhythmias (AF/AFL/AT) greater than 30 seconds (as documented by 24-hr Holter at 12-month follow-up) and on or off class I/III AADs. This measure is presented here as the number of participants, and the associated percentage of subjects (proportion * 100%) is also displayed as the result of an automatic calculation.

    Measured: 12 months post-procedure

  3. Number of Participants With AAD-Free Long-Term Success

    Freedom from all atrial arrhythmias (AF/AFL/AT) greater than 30 seconds (as documented by 24-hr Holter at 12-month follow-up) and off all class I/III AADs. This measure is presented here as the number of participants, and the associated percentage of subjects (proportion * 100%) is also displayed as the result of an automatic calculation.

    Measured: 12-month post-procedure

Secondary outcomes (9)
  1. Overall Procedure Time

    Defined as time from initial catheter insertion to final catheter removal. This is one measure of the amount of time it took for the physician to use invasive tools (catheters) during the procedure to investigate, diagnose, and treat the participant's heart condition.

    Measured: During Procedure

  2. Radiofrequency (RF) Time

    Defined as duration of time radiofrequency energy is delivered. This is a measure the amount of time the physician was actively applying treatment to the heart to treat the participant's heart condition.

    Measured: During Procedure

  3. Fluoroscopy Time

    Defined as total time subject is exposed to fluoroscopy. Fluoroscopy is a type of medical imaging that uses x-rays. This imaging is used by the physician to facilitate a safe and effective procedure. Less fluoroscopy time may help reduce the risk of issues related to x-ray exposure, however other factors such as fluroscopy intensity (not measured in this study) may also be important.

    Measured: During Procedure

  4. Mapping Time Associated With Mapping Arrhythmia

    Defined as the total cumulative mapping time and mapping time for the creation of each map (including any new or retrospective map created with Manual, AutoMap, and TurboMap mapping). As part of an ablation procedure to treat atrial fibrillation, some physicians create a map of the heart's electrical activity. The information in the map may be used by the physician to plan the treatment strategy. Mapping time provides a measure of how much time the physician spent creating, updating, and analyzing maps during the procedure. A short mapping time is not necessarily better or worse than a long mapping time, as other factors such as the amount and type of information gathered may also affect how useful the map is to the physician.

    Measured: During Procedure

  5. Number of Mapping Points Collected

    Defined as total number of mapping points collected for the creation of each map. As part of an ablation procedure to treat atrial fibrillation, some physicians create a map of the heart's electrical activity. The information in the map may be used by the physician to plan the treatment strategy. Number of mapping points collected is a measure of how much information was collected. A small number of mapping points collected is not necessarily better or worse than a large number of points, as other factors such as the amount of time spent and type of information gathered may also affect how useful the map is to the physician.

    Measured: During Procedure

  6. Number of Mapping Points Used

    Defined as the total number of mapping points used in each map. As part of an ablation procedure to treat atrial fibrillation, some physicians create a map of the heart's electrical activity. The information in the map may be used by the physician to plan the treatment strategy. Number of mapping points collected is a measure of how much information was collected, while number of mapping points used is a measure of how many such points were considered useful. A small number of mapping points used is not necessarily better or worse than a large number of points, as other factors such as the amount of time spent and type of information gathered may also affect how useful the map is to the physician.

    Measured: During Procedure

  7. Number of Used Mapping Points Per Minute

    Defined as the total number of mapping points used divided by the relative mapping time. As part of an ablation procedure to treat atrial fibrillation, some physicians create a map of the heart's electrical activity. The information in the map may be used by the physician to plan the treatment strategy. Mapping time is a measure of how much time the physician spent collecting, updating, and analyzing the information in the map. Number of mapping points collected is a measure of how much information was collected, while number of mapping points used is a measure of how many such points were considered useful. The number of used mapping points per minute is a measure of how efficient the mapping process is. A larger number of used mapping points per minute may be associated with a more efficient mapping process. Mapping efficiency may be of interest to a physician, however other factors such as the type of information gathered may also be of interest.

    Measured: During Procedure

  8. Substrate Characteristics Identified

    For each type of arrhythmogenic substrate this will be defined as the frequency of substrate type identified in cases that attempted to identify the specific substrate. As part of an ablation procedure to treat atrial fibrillation, some physicians create a map of the heart's electrical activity or use other tests to characterize the state, function, or health of certain areas of the heart tissue, and to localize certain areas that may be problematic (substrate). These localized characteristics may provide information to the physician that could be used to treat the participant's heart condition. This outcome measure lists common substrate characteristics and the number of subjects for which the characteristic was found or otherwise used as part of the treatment plan.

    Measured: During Procedure

  9. Ablation Strategy(s) Used

    Defined by both the type of map used to define ablation strategy and the frequency each ablation strategy/target was used by physicians. A physician may use one or more strategies to treat the participant's heart condition, including selectively burning (ablating) certain areas of the heart. This outcome measure lists common ablation strategies and the number of participants that received treatment based on each strategy.

    Measured: During Procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jul 2019
  2. Study start11 Sep 2019
  3. Primary completion13 Aug 2021
  4. Study completion13 Aug 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
200 participants (actual)
Target duration
12 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT04022954
Sponsor's protocol ID
CRD975
Status last verified
Oct 2023
First submitted
29 Jun 2019
Last updated
29 Mar 2024
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Paroxysmal Atrial Fibrillation and Persistent Atrial Fibrillation, run by Abbott Medical Devices at 15 sites in 5 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 15 sites in Japan, China, South Korea, Taiwan, Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 29 Mar 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Acute Success of RF Ablation After Electroanatomical Mapping With HD Mapping Catheters. (time frame: End of Procedure). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in